However, the ubiquity of macrophages in the body (Epelman et al., 2014) calls for the selective delivery of immunomodulatory agents, including STING agonists, to TAMs in the tumor to improve the efficacy of these agents and to avoid adverse immune effects. The gene discussed is STING1; the disease is neoplasm.